Search
All Clinical Trials
A listing of 23128 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
2437 - 2448 of 23128
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Investigating Epilepsy: Screening and Evaluation
Recruiting
Background:
Epilepsy affects about 1 percent of the U.S. population. Most people with epilepsy respond well to medicine, but some do not. Researchers want people who have diagnosed or suspected epilepsy to participate in ongoing studies. They want to learn more about clinical care for epilepsy. They want fellows and residents to learn more about the care of people with epilepsy.
Objectives:
To learn more about seizures and find ways to best treat people with drug-resistant epilepsy.
Eligibil... Read More
Gender:
ALL
Ages:
Between 8 years and 110 years
Trial Updated:
06/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Recruiting
The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/06/2025
Locations: Children's Hospital of Atlanta, Atlanta, Georgia +11 locations
Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Recruiting
The overall goal of the study is to establish valid clinical endpoint assessments for children with congenital myotonic dystrophy type 1 and develop biomarkers for the condition.
Gender:
ALL
Ages:
59 months and below
Trial Updated:
06/06/2025
Locations: University of California, Los Angeles, Los Angeles, California +4 locations
Conditions: Congenital Myotonic Dystrophy, CDM
LGMD R1 Natural History Study
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: University of California, Irvine, Orange, California +11 locations
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
Recruiting
The CAlcium and VAsopressin following Injury Early Resuscitation (CAVALIER) Trial is a proposed 4 year, double-blind, mutli-center, prehospital and early in hospital phase randomized trial designed to determine the efficacy and safety of prehospital calcium and early in hospital vasopressin in patients at risk of hemorrhagic shock.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: Allegheny Health Network, Pittsburgh, Pennsylvania +1 locations
Conditions: Trauma, Hemorrhage
Evaluate the Neurological Effects of EryDex on Subjects With A-T
Recruiting
This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangiectasia (A-T).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
06/06/2025
Locations: University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California +20 locations
Conditions: Ataxia Telangiectasia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Recruiting
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
06/06/2025
Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +53 locations
Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Recruiting
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/06/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +6 locations
Conditions: Neurofibromatosis Type 1
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
Recruiting
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare.
Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer
Emotional Awareness and Expression Therapy for Chronic Pain and Opioid Use Disorder
Recruiting
The study is intended to test whether a group-based Zoom behavioral treatment can help adults with chronic pain and opioid use disorder (OUD) learn effective strategies for reducing pain, disability and other problems that can come with these conditions (such as depression, anxiety, and difficulty managing emotions).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Chronic Pain, Opioid Use Disorder
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Recruiting
The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome. The main questions it aims to answer are:
* Does the combination drug exhibit hematological and nonhematological toxicity?
* Does the combination drug improve health status and reduce the number of days of hospitalization?
Participants will:
* Take tetrahydrouridine and decita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Montefiore Einstein Medical Center, Bronx, New York
Conditions: MDS
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Recruiting
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Gender:
MALE
Ages:
Between 40 years and 89 years
Trial Updated:
06/06/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
2437 - 2448 of 23128